Article

<i>in silico</i> Assessment of Antibody Drug Resistance to Bamlanivimab of SARS-CoV-2 Variant B.1.617

2021-05-14

Abstract excerpt

The highly infectious SARS-CoV-2 variant B.1.617 with double mutations E484Q and L452R in the receptor binding domain (RBD) of SARS-CoV-2’s spike protein is worrisome. Demonstrated in crystal structures, the residues 452 and 484 in RBD are not in direct contact with interfacial residues in the angiotensin converting enzyme 2 (ACE2). This suggests that albeit there are some possibly nonlocal effects, the E484Q and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7258eb78-f34b-5080-98b1-b684dd1d2ad9
DOI: 10.1101/2021.05.12.443826

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>in silico</i> Assessment of Antibody Drug Resistance to Bamlanivimab of SARS-CoV-2 Variant B.1.617DOI 10.1101/2021.05.12.443826Read

Structure-Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda.Semantic proximity Read

SARS-CoV-2 variants and bebtelovimab: immune escape mechanisms revealed by computational studies.Semantic proximity Read

Impact of E484Q and L452R Mutations on Structure and Binding Behavior of SARS-CoV-2 B.1.617.1 Using Deep Learning AlphaFold2, Molecular Docking and Dynamics Simulation.Semantic proximity Read

Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies.Semantic proximity Read

Rapid <i>in silico</i> design of antibodies targeting SARS-CoV-2 using machine learning and supercomputingSemantic proximity Read

A novel peptide analogue of spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico approach through molecular docking, molecular dynamics simulation and MM-PB/GBSA calculationsSemantic proximity Read

E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studiesSemantic proximity Read

Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodiesSemantic proximity Read

Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodiesSemantic proximity Read

E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies.Semantic proximity Read

SARS-CoV-2 Spike Protein's Structural Dynamics Affect the Activity of the Bebtelovimab Antibody.Semantic proximity Read

Bebtelovimab-bound SARS-CoV-2 RBD mutants: resistance profiling and validation with escape mutations, clinical results, and viral genome sequences.Semantic proximity Read